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Abstract 
 
Background 
Identifying the phenotypic manifestations of increased genetic liability for depression (MDD) and 
bipolar disorder (BD) can enhance understanding of their aetiology. The polygenic risk score (PRS) 
derived using data from genome-wide-association-studies can be used to explore how genetic risk is 
manifest in different samples.  
 
Aims 
In this systematic review, we review studies that examine associations between the MDD and BD 
polygenic risk scores and phenotypic outcomes.  
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Methods 
Following PRISMA guidelines, we searched EMBASE, Medline and PsycINFO (from August 2009 – 14th 
March 2016) and references of included studies. Study inclusion was based on predetermined 
criteria and data were extracted independently and in duplicate.  
 
Results  
Twenty-five studies were included. Overall, both polygenic risk scores were associated with other 
psychiatric disorders (not the discovery sample disorder) such as depression, schizophrenia and 
bipolar disorder, greater symptom severity of depression, membership of a creative profession and 
greater educational attainment. Both depression and bipolar polygenic risk scores explained small 
amounts of variance in most phenotypes (<2%).  
 
Limitations  
Many studies did not report standardised effect sizes. This prevented us from conducting a meta-
analysis. 
 
Conclusions 
Polygenic risk scores for BD and MDD are associated with a range of phenotypes and outcomes. 
However, they only explain a small amount of the variation in these phenotypes. Larger discovery 
and adequately powered target samples are required to increase power of the PRS approach. This 
could elucidate how genetic risk for bipolar disorder and depression is manifest and contribute 
meaningfully to stratified medicine. 
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1. Introduction 
 
Mood disorders (major depressive disorder (MDD) and bipolar disorder (BD)) are common, highly 
heritable psychiatric conditions as evidenced by twin, adoption and family studies (Bienvenu et al., 
2011; Oswald et al., 2003; Shih et al., 2004; Sullivan et al., 2000).  Family history of a mood disorder 
is a strong risk factor for future development of a mood disorder. High-risk studies of offspring of 
parents with a mood disorder have shown that offspring have an increased lifetime risk for BD (Duffy 
et al., 2014) or MDD when compared to controls (Rice et al., 2002). Additionally, they are also at 
increased risk for developing other psychiatric disorders (Rasic et al., 2014). Previously, information 
about how genetic risk for these disorders was manifest in the population was obtained from high-
risk studies that followed up offspring of parents with these disorders. However, a major limitation 
of these high-risk studies was the relatively small sample sizes, which meant studies were 
inadequately powered to detect small effect sizes.   
 
The advent of genome-wide association studies (GWAS) has revolutionised identification of genetic 
variants contributing to psychiatric disorders. GWAS technology can examine many genetic variants 
in the genome simultaneously, without an a priori hypotheses. Approaches have been developed to 
harness this information, allowing us to study how individuals with different burdens of genetic risk 
differ from one another. Through GWAS, several risk variants associated with MDD and BD have 
been identified (Major Depressive Disorder Working Group of the Psychiatric Genetics Consortium et 
al., 2017; Sklar et al., 2011; Stahl et al., 2017; Sullivan, 2013). Though the number of risk variants is 
fewer than for schizophrenia (SZ) (Purcell et al., 2009; Ripke et al., 2014), this is likely due to the 
smaller discovery samples used in the GWAS analyses, and the lower heritability of MDD compared 
to schizophrenia (SZ). Whilst individual single nucleotide polymorphisms (SNPs) have very small 
effect on disease risk, summing the weighted allelic dosage across all SNPs, creating a single 
polygenic risk score (PRS) has enabled the exploration of how genetic risk is manifest directly in 
individuals across different populations (Figure 1) (Wray et al., 2014).  
 
Since the first GWAS were published, many studies have examined whether the MDD-PRS or BD-PRS 
are associated with a range of different phenotypes and outcomes. Though other methods such as 
linkage disequilibrium (LD) score regression or genomic residual maximum likelihood (GREML) 
analysis exist to examine genetic correlation, the focus of this systematic review was to identify and 
4 
 
summarise studies that used the PRS approach to examine how genetic risk for MDD and BD is 
manifest in clinical and population-based samples.
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2. Methods 
 
We undertook a systematic review following Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Moher et al., 2009) (Supplementary Table 1).   
 
2.1 Search strategy  
 
2.1.1 Inclusion/exclusion criteria  
 
We included articles that examined associations between the PRS (derived from GWAS data of 
participants with a diagnosis of MDD or BD) and a measurable phenotype. We excluded 
neuroimaging outcomes as the complexity of this field is beyond the scope of this systematic review. 
Articles reporting associations between the MDD-PRS/ BD-PRS with a diagnosis of MDD or BD 
respectively were not included. We required articles to be in peer reviewed journals and written in 
English (see Supplementary Table 2 for inclusion/exclusion criteria).  
 
2.1.2 Data sources 
 
We searched EMBASE, Medline and PsychINFO databases from 06/08/2009 to 14/03/2016. We also 
hand searched references of the articles included.  
 
2.1.3 Search terms and delimiters  
 
We searched for articles using the terms “depression/bipolar (or variations of)” AND “polygenic (or 
variations of)”. Our full search strategy terms are listed in Supplementary List 1.   
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2.1.4 Data collection and analysis 
 
2.1.4.1 Selection of studies 
 
In keeping with our previous systematic review (Mistry et al., 2017), after duplicates were removed, 
1043 articles remained (see Figure 2 for flow diagram). One author, (S.M.) screened the title and 
abstract. If it was unclear whether the paper was relevant, or if the abstract was unavailable, we 
retrieved the full-text article. Two authors independently reviewed each full-text article and checked 
them against the inclusion criteria. A third author resolved disagreements. We extracted relevant 
information using a data extraction form (see Supplementary Table 3). We used a narrative 
approach to summarise results as most studies did not report standardised effect sizes (or provide 
data that would allow us to calculate these) as required for conducting a meta-analysis. 
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3. Results 
 
This review includes 25 articles that examined associations between the MDD-PRS/BD-PRS and a 
measurable phenotype (see Table 1 for a summary of associations with broad phenotypic 
outcomes). Most studies derived their PRS from the same discovery sample: the first GWAS from the 
Psychiatric Genetics Consortium (PGC) for MDD and BD (Sklar et al., 2011; Sullivan, 2013). Individual 
studies used different p-value thresholds (PTs) to assess the relationship between genetic risk for the 
disorder and phenotype or outcome (see Supplementary Tables 4-6). Most studies were of 
White/Caucasian adults of European ancestry.   
 
3.1 Studies examining phenotypic associations with both the MDD-
PRS and BD-PRS  
 
Several studies used both the MDD and BD polygenic risk scores to examine associations between 
genetic risk and a measurable phenotype.  
 
3.1.1 Associations with psychiatric disorders  
 
Using data from the PGC, both the MDD and BD polygenic risk scores were strongly associated with 
SZ (strongest PT<0.4; p=1x10-16; strongest PT<0.3, p=1x10-50 respectively). However, there was no 
association between the MDD-PRS and ADHD or ASD across any PT (no p-values reported), and weak 
evidence for associations between the BD-PRS and ADHD or ASD (strongest PT<0.4, p<0.05; strongest 
PT<0.001, p<0.05 respectively). The MDD-PRS was associated with BD (strongest PT<0.5, p=1x10-12) 
and the BD-PRS was associated with MDD (strongest PT<0.5, p=1x10-16) (Cross-Disorder Group of the 
Psychiatric Genomics, 2013). 
A study using data from the Australian Twin Registry (ATR) and Midwest Alcohol Research Centre 
found no evidence that the MDD-PRS was associated with seasonal affective disorder (SAD) 
(strongest at PT<0.01, p=0.25), but there was some evidence of association between the BD-PRS and 
SAD (strongest PT<0.1, p=0.004) (Byrne et al., 2015). 
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Both the BD and MDD polygenic scores were associated with SZ, either when comparing those with 
SZ and a positive history of psychotic illness to controls (strongest at PT<1, 1-sided p=7.11x10-149 and 
PT<1, 1-sided p=1.49x10-59 respectively) or when comparing those with SZ and a negative family 
history of psychotic illness to controls (strongest at PT<1, 1-sided p<1x10-300 and PT<1, 1-sided 
p=9.95x10-254 respectively) (Bigdeli et al., 2015).  
Finally, a higher BD-PRS was associated with post-traumatic stress disorder (PTSD) (strongest PT<0.3, 
p= 0.028), but the MDD-PRS was not associated at any PT (no statistics provided) in the Marine 
Resilience Studies (Nievergelt et al., 2015). 
 
3.1.2 Association with other phenotypes 
 
Both the MDD and BD polygenic risk scores were also associated with: i) greater episode count of 
MDD in individuals with MDD (strongest PT<0.4, p <0.001; strongest PT<0.2, p=0.015 respectively), 
particularly in individuals with MDD and a positive family history of MDD (strongest PT<0.4, p =0.01; 
strongest PT<0.2, p=0.004 respectively) using data from the RADIANT sample (Ferentinos et al., 
2014), and ii) a family history of psychotic illness in individuals with SZ from the PGC-1-SZ GWAS 
(strongest PT<0.4, one-sided p=0.011; strongest PT <0.2, one-sided p=0.04 respectively) (Bigdeli et al., 
2015).  
In a combined analysis using data from four different samples (Mullins et al., 2014), the MDD-PRS 
was associated with a greater number of suicide attempts (strongest PT<0.3, p =0.013), whilst the 
BD-PRS was not (strongest PT<0.1; no p-value reported).  
Using data from the National Institute of Neurological Disorders and Stroke (NINDS) sample, the 
MDD-PRS was higher in Parkinson’s disease (PD) cases than controls (no PT reported; p=0.001; 
AUC=0.52), but the BD-PRS was not (no PT or p-value reported; AUC=0.5) (Schulze et al., 2014).  
Finally, whilst neither the MDD or BD polygenic risk scores were associated with measures of latent 
inhibition (ASSR, P3 latency or P50 ratio), there was strong evidence of an association between the 
BD-PRS and P3 amplitude (strongest PT<1x10-5; p=0.005) in a sample of individuals with psychotic 
illness and controls (Hall et al., 2015). 
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3.2 Studies examining phenotypic associations with the MDD-PRS  
 
3.2.1 MDD-PRS and psychiatric phenotypes 
 
Studies reported associations between the MDD-PRS and: i) greater chronicity of depressive 
symptoms (no p-value reported) in the Health and Retirement Study (HRS) sample (Levine et al., 
2014), ii) higher Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) scores in both the 
Rotterdam Study of Anxiety Disorder Case-Control sample (strongest PT<0.5, p=0.0025) and the 
Erasmus Ruchpen Family (ERF) sample (strongest PT<0.01, p=0.01) (Demirkan et al., 2011) and iii) 
higher General Health Questionnaire (GHQ) scores (strongest PT<0.05; p=9x10-6) and neuroticism 
(strongest PT<1. p=1x10-4) in the Generation Scotland: The Scottish Family Health Study (GS:SFHS) 
(Clarke et al., 2015). 
 
3.2.2 MDD-PRS and other phenotypes 
 
There was no consistent evidence of associations between the MDD-PRS and stressful life events 
(SLE) in the RADIANT samples, varying by both type of SLE (dependent or independent) and MDD 
case/control status (Mullins et al., 2016). There was also inconsistent evidence of associations 
between the MDD-PRS and childhood trauma (CT) in RADIANT, with opposite patterns of association 
in MDD cases compared to the controls. Furthermore, the pattern of association across MDD cases 
and controls in RADIANT was in the opposite direction to that within MDD cases and controls in the 
combined Genetics of Recurrent Early-Onset Depression (GenRED) and Depression Genes Networks 
(DGN) (Peyrot et al., 2014).  
Finally, the MDD-PRS was associated with higher body mass index (BMI) (strongest PT<0.01, p=0.01) 
in the GS:SFHS, which did not survive correction for multiple testing (no statistics reported) (Clarke 
et al., 2015). 
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3.3 Studies examining phenotypic associations with the BD-PRS  
 
3.3.1 BD-PRS and BD symptoms/severity 
 
The BD-PRS was associated with a manic symptom factor (strongest PT<0.3, p=0.003), but not with 
depressive, positive or negative symptom factors across any PT (no statistics reported) in individuals 
with SZ drawn from the PGC-1-SZ GWAS (Ruderfer et al., 2014).  
There was very weak evidence that the BD-PRS was associated with a positive history of psychosis in 
individuals with BD (strongest PT<0.05, p=0.079) using data from the Thematically Organised 
Psychosis sample (Aminoff et al., 2015), and with decreased paranoia (strongest PT<0.5, one-sided 
p=0.064) and decreased anhedonia (one-sided p=0.048). However, the BD-PRS was not associated 
with parent-rated negative symptoms, grandiosity, cognitive/disorganization and hallucinations in 
adolescents from the population-based Longitudinal Experiences and Perceptions (LEAP) study 
(Sieradzka et al., 2014). 
The BD-PRS was not associated with antidepressant response in individuals with MDD treated with 
Selective Serotonin Reuptake Inhibitors (SSRIs) (strongest PT<0.05, p=0.613), Noradrenaline 
Reuptake Inhibitors (NRIs) (strongest PT<0.1, p=0.168), or either antidepressant (strongest PT<0.3, 
p=0.623) in the New Medications in Depression and Schizophrenia sample. Neither was the BD-PRS 
associated with response to citalopram (strongest PT<0.3, p=0.826) in the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) sample (Tansey et al., 2014).  
When combining the NESDA and Netherlands Twin Registry (NTR) samples, the BD-PRS was 
associated with MDD (strongest PT<0.5, p=0.001) and both severe typical (strongest PT<0.5; p=0.018) 
and atypical MDD (strongest PT<0.1, p=0.032) (Milaneschi et al., 2016). 
There was inconsistent evidence of associations between the BD-PRS and characteristics of 
depression (including severity, age of onset, history of suicide attempt, recurrence, and 
atypicality) within a multivariate framework, or with subclinical mania in the STAR*D, 
Mannheim and NESDA samples (Wiste et al., 2014).  
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3.3.2 BD-PRS and other psychopathology 
 
In data from a Norwegian sample, the BD-PRS was i) higher in SZ-spectrum cases compared to 
controls without SZ, BD or MDD (strongest PT<0.05; p=0.01), but not in SZ-spectrum cases compared 
to BD-spectrum cases (strongest PT<0.05; p=0.13), and ii) not associated with a lifetime history of 
psychosis in BD-spectrum cases compared to controls (no statistics provided) (Tesli et al., 2014). 
Using data from i) the combined NESDA/NTR samples and ii) the Queensland Institute of Medical 
Research (QIMR) sample, a study reported associations between the BD-PRS and post-partum 
depression (strongest PT<0.001, p=0.004 and PT<0.1, p = 3.04x10-5 respectively) (Byrne et al., 2014) 
In the GAIN MDD sample, the BD-PRS was higher in MDD cases compared to controls (no PT 
reported, p = 7.32x10-7) with modest diagnostic accuracy AUC=0.55, and was also higher in SZ cases 
compared to controls in the GAIN-SZ sample (no PT reported, p=2.9x10-9; AUC=0.56) (Schulze et al., 
2014). 
Finally, a higher BD-PRS was found in ADHD cases compared to controls (strongest PT<0.5; p=0.052) 
using combined data from UK community child psychiatry and paediatric clinics and from Dublin 
Ireland (Hamshere et al., 2013). 
 
3.3.3 BD-PRS and other phenotypes 
 
In an Icelandic general population study, the BD-PRS was associated with creativity (strongest at 
PT<0.2; p=5.2x10-6), number of years in school (p=4.8x10-9) and having a university degree (p=5.2x10-
7) (Power et al., 2015). 
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4. Discussion 
 
To the best of our knowledge, this is the first paper to systematically review how genetic risk for 
MDD and BD is associated with a broad range of phenotypic outcomes. Other reviews have focussed 
on the application of PRS methodology to psychiatric disorders, particularly SZ (Wray et al., 2014). 
More recently we have reported phenotypes associated with genetic risk for SZ (Mistry et al., 2017). 
Higher MDD and BD polygenic risk scores were associated with increased risk of different 
psychopathologies. Typically, R2 values for other psychiatric disorders (0.5-2%) were greater than for 
other phenotypes examined (most <1%). One exception is a study that reported that approximately 
6% to 13% of the variance for SZ was explained by the MDD-PRS, and 17% to 22% by the BD-PRS 
(depending on the presence or absence of a family history of psychotic illness. However, these 
estimates seem likely to be over-estimates given that the SZ-PRS only explained 12% to 13% of the 
variance for SZ in this study (Bigdeli et al., 2015).  
    
4.1 Psychiatric outcomes 
 
Associations between genetic risk for MDD/BD and psychiatric disorders was stronger for disorders 
typically presenting in adulthood rather than in childhood. Associations between the MDD-PRS and 
BD-PRS with SZ is consistent with evidence of pleiotropy across these disorders (Gale et al., 2016). 
Those with MDD who also have psychotic symptoms or a family history of psychotic illness likely 
index individuals with more severe forms of MDD (Park et al., 2014; Parker et al., 2013). 
There was no evidence the MDD-PRS was associated with SAD (Byrne et al., 2015). However, 
associations between both the BD and SZ polygenic scores and SAD in the same study have been 
found using risk scores derived from larger GWAS discovery data sets than for MDD, suggesting that 
low power may be a likely explanation for this lack of association (Dudbridge, 2013).  
 
4.2 Other psychopathology 
 
Both the MDD-PRS and BD-PRS were associated with greater episode count of MDD, the latter 
particularly in those who also had a family history of MDD (Ferentinos et al., 2014). Furthermore, 
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associations between the BD-PRS and early age of onset of MDD (<26 years) has been reported more 
recently (Power et al., 2017; Verduijn et al., 2017). These genetic study findings are also consistent 
with previous epidemiological studies showing that greater recurrence of MDD, presence of a family 
history of MDD, and early age of onset might index individuals who have an underlying ‘latent BD’ 
rather than having MDD (i.e. are at higher risk of transitioning from MDD to BD diagnoses than those 
without these characteristics) (Benazzi, 2006).  
The MDD-PRS was also associated with neuroticism in the Generation Scotland: The Scottish Family 
Health Study (Clarke et al., 2015), a finding also shown in another population based study, the UK 
Biobank (Gale et al., 2016). Neuroticism is robustly associated with increased risk for developing 
MDD (Hakulinen et al., 2015). Taken together, data from both genetic and epidemiological studies 
would suggest that within the general population, genetic risk for MDD can manifest as personality 
traits such as neuroticism.  
Genetic risk for BD was not associated with antidepressant response (though effects on response to 
tricyclics or monoamine oxidases has not yet been investigated). More recently, a study reported no 
association between the MDD-PRS and antidepressant response in individuals with MDD using the 
same classes of antidepressant used by Tansey and colleagues (Garcia-Gonzalez et al., 2017). Taken 
together, this suggests that neither genetic risk for BD or MDD is currently helpful in determining 
whether an individual will respond better to a particular class of antidepressant. It is likely that 
polygenic risk scores based on gene pathways are more likely to determine whether antidepressant 
response can be determined using genetic risk for BD or MDD, or exploration of whether the MDD 
and BD PRSs are associated with tricyclics or monoamine oxidases. 
 
4.3 Other phenotypes 
 
Associations between the MDD-PRS and CT were inconsistent, with studies reporting opposing 
patterns of association (Mullins et al., 2016; Peyrot et al., 2014), likely reflecting the problems 
inherent in studying how patterns differ across sub-groups (Zammit et al., 2010). 
Increased genetic risk for BD was associated with creativity and greater educational attainment 
(Power et al., 2015). Some epidemiological studies report positive associations between higher 
childhood IQ and BD (Koenen et al., 2009; Smith et al., 2015) and greater educational attainment 
and BD (MacCabe et al., 2010; Vreeker et al., 2016). However, others looking at adolescent or adult 
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IQ report no association with BD (Reichenberg et al., 2002; Zammit et al., 2004) and poorer 
educational attainment with BD (Glahn et al., 2006; Mojtabai et al., 2015; Vonk et al., 2012).   
Similarly, cognitive impairments throughout all mood states of BD manifest in young adults (Kurtz 
and Gerraty, 2009; Martino et al., 2016), rather than in the premorbid phase (Martino et al., 2015). 
However, BD is a heterogeneous disorder: not all of those affected go on to have cognitive deficits 
(Martino et al., 2008). 
Assessments of creativity in those with BD can be studied using neuroimaging. During creative tasks, 
those with BD have increased functional connectivity in the fronto-parietal network (Goya-
Maldonado et al., 2016), including dorosolateral prefrontal (Boccia et al., 2015) and medial 
prefrontal cortices (Jung et al., 2013) compared to controls. As these areas of the brain are typically 
involved in executive functioning and planning, these neuroimaging findings might explain increased 
openness to experience, elevated impulsivity and increased desire to engage in more complex 
activities in those with BD. Whilst currently limited by refinement of neuroimaging methods, sample 
sizes, and validity of BD-PRS, it is feasible that the PRS approach, especially if based on gene-
pathways, could inform the biology of specific cognitive outcomes and imaging parallels of these. 
Similar approaches such as LD score regression also suggest similar findings when examining genetic 
correlations between adult psychiatric disorders, educational attainment and personality traits such 
as neuroticism (Bulik-Sullivan et al., 2015; Verneri et al., 2016). 
 
4.4 Implications  
 
Overall, the results presented in this systematic review highlight that the polygenic risk scores for 
MDD and BD explain a small proportion of the variance for all phenotypes (<2%), with the exception 
of the study by Bigdeli et al. (2015). The variance explained will likely increase as discovery sample 
sizes increase (Dudbridge, 2013), though this may still be limited as the PRS does not capture rare 
SNP or copy number variants contributions to variance.  
At the present time, the PRS approach is not useful for informing clinical practice or pharmacological 
interventions. However, as predictive utility increases with larger discovery and adequately powered 
target samples, the PRS, alongside other approaches, could help inform stratified medicine. 
Our review also shows that genetic risk for MDD and BD is manifest in the adult population as a 
broad range of psychopathologies. As the literature on genetic risk scores for MDD and BD 
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associations with childhood psychopathologies is extremely limited, it is difficult to determine how 
or whether genetic risk influences phenotypes earlier in development. 
 
4.5 Strengths and limitations  
 
A major strength to this systematic review is that we used a comprehensive search strategy to 
reduce the likelihood of omitting eligible studies. In addition, we did not limit this review to a specific 
sampling framework or research design e.g. clinical samples or longitudinal studies). We also 
included studies investigating a range of phenotypes and outcomes, providing a board overview of 
how genetic risk for bipolar and depression can manifest. However, the inconsistency in the 
reporting of results across studies meant that only a narrative approach to this review was feasible, 
and assessment of publication bias was not possible. We excluded neuroimaging results as they are 
significantly more complex to summarise and are therefore not able to comment on how depression 
or bipolar genetic risk relates to imaging phenotypes. Studies not published in English-language 
journals will also have been missed.  
We identified a number of limitations of studies included in this review. This made it difficult to put 
their findings in context. Problems included inadequate descriptions of sample ascertainment, the 
strength of evidence incorrectly interpreted based on one-sided p-values, and failure to report 
standardised effect sizes or confidence intervals to permit comparison across studies. In order to 
improve interpretation and comparison between studies, we have developed a reporting framework 
for researchers to use (Mistry et al., 2017). 
An important limitation of the PRS approach is that it is based on the assumption that both target 
and discovery samples are independent of each other: any overlap will inflate the risk estimates. 
Furthermore, when interpreting the findings from PRS analyses, both an adequately powered target 
sample size and a large discovery sample size are required to optimise association testing and risk 
prediction (Dudbridge, 2013); so whilst most studies were adequately powered to detect small-
moderate effect sizes (OR=1.2-1.5 per SD of the PRS), this is based on the assumption of no 
measurement error in the PRS.  
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4.6 Conclusions 
 
At present, the PRS approach explains very little of the variance in phenotypes, with the greatest 
variance explained being for other psychiatric disorders. This is the first review attempting to collate 
information on how the PRS approach has informed our understanding of a variety of phenotypes in 
terms of association with depression and bipolar disorder genetic risk. Future studies will benefit 
from larger sample sizes from which to derive PRS, adequately powered target sample sizes, well-
validated phenotypic measures and more robust ways of reporting PRS associations with 
phenotypes.  
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